BioCentury | Aug 17, 2018
Finance

Vaccine volatility

The last two weeks have not been kind to biopharma companies listed on Chinese exchanges, and Thursday’s announcements regarding the resignations of officials over a vaccine scandal could further dampen sentiment. Earlier this month, the...
BioCentury | Mar 25, 2017
Finance

Solasia goes to market

After becoming the first Japanese biotech to go public in 18 months, Solasia Pharma K.K. (Tokyo:4597) plans to use the proceeds to prepare to launch its first products in China. Solasia raised ¥3.6 billion ($32...
BC Week In Review | Dec 7, 2015
Company News

Solasia, Lee’s Pharmaceutical Holdings Ltd. deal

Solasia granted Lee’s exclusive rights to commercialize Sancuso granisetron patch to treat chemotherapy-induced nausea and vomiting (CINV) in China, excluding Hong Kong and Macau. Solasia retains rights to promote the transdermal serotonin (5-HT3) receptor antagonist...
BC Week In Review | Nov 25, 2013
Company News

Solasia, Kyowa Hakko Kirin sales and marketing update

Kyowa's Kyowa Hakko Kirin Taiwan Co. Ltd. subsidiary launched Sancuso granisetron patch in Taiwan to treat chemotherapy-induced nausea and vomiting. The reimbursed price of Sancuso is NT$2,072 ($70.04) per 3.1 mg/24 hour patch. The product...
BC Week In Review | Nov 4, 2013
Clinical News

Sancuso granisetron patch regulatory update

Kyowa disclosed in its 3Q13 earnings that in August Singapore approved granisetron patch to treat chemotherapy-induced nausea and vomiting. The transdermal serotonin (5-HT3) receptor antagonist is already approved as Sancuso in the U.S., EU and...
BioCentury | May 27, 2013
Strategy

Royalty pain or gain

Elan Corp. plc shareholders have a lot to consider before a June 17 meeting to decide the fate of the biotech. Investors can walk away after pocketing the $6.4 billion proposed by suitor Royalty Pharma...
BioCentury | Mar 18, 2013
Strategy

Japan's biggest biotech

Japanese pharmaceutical companies have historically been thought of as stodgy, insular and opaque, but that is changing fast. One year into the job, Kyowa Hakko Kirin Co. Ltd. 's CEO is building his company along...
BC Week In Review | Feb 11, 2013
Clinical News

Sancuso granisetron patch regulatory update

Kyowa said in its 2012 earnings that in October Taiwan approved Sancuso granisetron patch to treat nausea and vomiting induced by chemotherapy. The transdermal serotonin (5-HT3) receptor antagonist is already approved in the U.S. and...
BioCentury | Jul 2, 2012
Finance

2Q Stock Wrap-Up: Magic in mid-caps

Mid-caps performed best last quarter, with four companies gaining more than 50%. Other segments largely held on to their 1Q gains, except for companies valued below $200 million, which fell 15% in the quarter and...
BC Week In Review | Apr 30, 2012
Clinical News

Sancuso granisetron patch regulatory update

The European Commission approved an MAA from Kyowa's ProStrakan Group plc subsidiary for Sancuso granisetron to prevent nausea and vomiting associated with moderately or highly emetogenic chemotherapy. The transdermal serotonin (5-HT3) receptor antagonist was approved...
Items per page:
1 - 10 of 67